SEC Company Response from Arcutis Biotherapeutics, Inc. (ARQT) (CIK 0001787306) (ARQT) — Jan 28, 2020
Arcutis Biotherapeutics, Inc. (ARQT) (CIK 0001787306)
Date: Jan. 28, 2020 · CIK: 0001787306 · Accession: 0001193125-20-016868
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-235806
Letter
January 28, 2020
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
Attention: Julia Griffith
Dietrich King
Christine Torney
Angela Connell
Re: Arcutis Biotherapeutics, Inc. Registration Statement on Form S-1 (File No. 333-235806) originally filed January 6, 2020, as amended.
Requested Date: January 30, 2020
Requested Time: 4:00 PM Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as the representatives of the several underwriters, hereby join in the request of Arcutis Biotherapeutics, Inc. (the “Registrant”) that the Securities and Exchange Commission take appropriate action to declare the above-captioned Registration Statements on Form S-1 effective at the “Requested Date” and “Requested Time” set forth above, or as soon thereafter as practicable, or at such other time as the Registrant or its outside counsel, Fenwick & West LLP, may request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Pursuant to Rule 460 under the Act, we, as the representatives of the several underwriters, wish to advise you that between January 21, 2020 through the date hereof we have distributed approximately 3,276 copies of the Registrant’s Preliminary Prospectus dated January 21, 2020 to prospective underwriters, dealers, institutional investors and others.
We, the undersigned, as the representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
* * *
Sincerely,
GOLDMAN SACHS & CO. LLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP January 28, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Julia Griffith Dietrich King Christine Torney Angela Connell Re: Arcutis Biotherapeutics, Inc. Registration Statement on Form S-1 (File No. 333-235806) originally filed January 6, 2020, as amended. Requested Date: January 30, 2020 Requested Time: 4:00 PM Eastern Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as the representatives of the several underwriters, hereby join in the request of Arcutis Biotherapeutics, Inc. (the “Registrant”) that the Securities and Exchange Commission take appropriate action to declare the above-captioned Registration Statements on Form S-1 effective at the “Requested Date” and “Requested Time” set forth above, or as soon thereafter as practicable, or at such other time as the Registrant or its outside counsel, Fenwick & West LLP, may request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Pursuant to Rule 460 under the Act, we, as the representatives of the several underwriters, wish to advise you that between January 21, 2020 through the date hereof we have distributed approximately 3,276 copies of the Registrant’s Preliminary Prospectus dated January 21, 2020 to prospective underwriters, dealers, institutional investors and others. We, the undersigned, as the representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. * * * Sincerely, GOLDMAN SACHS & CO. LLC COWEN AND COMPANY, LLC As representatives of the several Underwriters GOLDMAN SACHS & CO. LLC By: /s/ Sonia M. Gupta Name: Sonia M. Gupta Title: Managing Director COWEN AND COMPANY, LLC By: /s/ Bill Follis Name: Bill Follis Title: Managing Director